JP4402173B2 - Ｄｈａ―薬剤複合体 - Google Patents

Ｄｈａ―薬剤複合体 Download PDF

Info

Publication number
JP4402173B2
JP4402173B2 JP54281197A JP54281197A JP4402173B2 JP 4402173 B2 JP4402173 B2 JP 4402173B2 JP 54281197 A JP54281197 A JP 54281197A JP 54281197 A JP54281197 A JP 54281197A JP 4402173 B2 JP4402173 B2 JP 4402173B2
Authority
JP
Japan
Prior art keywords
hydrochloride
sodium
agent
acid
sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54281197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514405A (ja
JP2000514405A5 (enExample
Inventor
オー． ブラッドレー，マシューズ
イー． シャスア，ビクトール
エル． ウェッブ，ナイジェル
エス． スウィンデル，チャールズ
Original Assignee
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルイトポルド・ファーマシューティカルズ・インコーポレーテッド filed Critical ルイトポルド・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2000514405A publication Critical patent/JP2000514405A/ja
Publication of JP2000514405A5 publication Critical patent/JP2000514405A5/ja
Application granted granted Critical
Publication of JP4402173B2 publication Critical patent/JP4402173B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
JP54281197A 1996-05-22 1997-05-22 Ｄｈａ―薬剤複合体 Expired - Fee Related JP4402173B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/651,312 US5795909A (en) 1996-05-22 1996-05-22 DHA-pharmaceutical agent conjugates of taxanes
US08/651,312 1996-05-22
PCT/US1997/008867 WO1997044063A2 (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates

Publications (3)

Publication Number Publication Date
JP2000514405A JP2000514405A (ja) 2000-10-31
JP2000514405A5 JP2000514405A5 (enExample) 2005-02-10
JP4402173B2 true JP4402173B2 (ja) 2010-01-20

Family

ID=24612392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54281197A Expired - Fee Related JP4402173B2 (ja) 1996-05-22 1997-05-22 Ｄｈａ―薬剤複合体

Country Status (10)

Country Link
US (3) US5795909A (enExample)
EP (2) EP0909183B1 (enExample)
JP (1) JP4402173B2 (enExample)
AT (1) ATE273025T1 (enExample)
AU (1) AU725759B2 (enExample)
CA (1) CA2255614C (enExample)
DE (1) DE69730217T2 (enExample)
DK (1) DK0909183T3 (enExample)
ES (1) ES2222514T3 (enExample)
WO (1) WO1997044063A2 (enExample)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
CA2291074C (en) * 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US6426369B1 (en) * 1997-09-17 2002-07-30 Eisai Co., Ltd. Oxethazaine as antimicrobial agent
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
CA2306024C (en) * 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
WO1999036098A1 (en) * 1998-01-13 1999-07-22 Suntory Limited Antibacterial composition for topical administration containing antibiotics
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
KR100536783B1 (ko) * 1998-07-28 2005-12-14 다케다 야쿠힌 고교 가부시키가이샤 급속 붕해성 고체 제제
KR100396171B1 (ko) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
EP1147879B8 (en) * 1999-01-29 2008-12-24 Takeda Pharmaceutical Company Limited Compressing mallet with coating treatment
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
KR20020000147A (ko) * 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
WO2000068229A2 (en) * 1999-05-07 2000-11-16 Wockhardt Limited (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
KR100518986B1 (ko) * 1999-11-15 2005-10-06 파르마 마르, 에스.에이. 아플리딘을 사용하여 암을 치료하는 방법
US20020045606A1 (en) * 1999-12-02 2002-04-18 Reddy Satyanarayana G. Esters of vitamin D3 and uses thereof
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
AU2001230994A1 (en) 2000-01-19 2001-07-31 The United States of America, represented by The Secretary, Department of Health & Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
RO121270B1 (ro) * 2000-02-02 2007-02-28 Florida State University Research Foundation, Inc. Taxani substituiţi cu esteri în poziţia c10, ca agenţi antitumorali
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US6452024B1 (en) 2000-02-22 2002-09-17 Chaichem Pharmaceuticals International Process for extraction and purification of paclitaxel from natural sources
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6392055B1 (en) 2000-07-19 2002-05-21 The University Of Pittsburgh Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6884777B1 (en) 2000-11-14 2005-04-26 The Nemours Foundation Method for treating respiratory distress syndrome
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
MXPA04002912A (es) * 2001-09-27 2004-07-05 Univ Ramot Farmacos anti-psicoticos conjugados y usos de ellos.
US6730667B2 (en) * 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
CA2466869C (en) * 2001-11-29 2010-01-19 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
CA2472678C (en) * 2002-01-04 2013-12-03 Sound Pharmaceuticals Incorporated Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
AU2003235931A1 (en) * 2002-05-13 2003-11-11 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040002663A1 (en) * 2002-06-26 2004-01-01 Reeves William H. Method and system for use in detecting a cancerous and precancerous pathology
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US6759539B1 (en) 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
CA2523197C (en) * 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
EP1636335B1 (en) * 2003-05-28 2012-07-11 Mito Tek, LLC Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
CA2537180A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005042539A1 (en) * 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
AU2004285529A1 (en) * 2003-10-30 2005-05-12 The Research Foundation of University of New York York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
GB0326180D0 (en) * 2003-11-11 2003-12-17 Leuven K U Res & Dev Biocompatible coating of medical devices
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
PA8625301A1 (es) 2004-03-05 2006-06-02 Univ Florida State Res Found Taxanos con sustituyente lactiloxilo en el c7
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
CN101044200A (zh) * 2004-09-24 2007-09-26 巴尔的摩马里兰大学 治疗有机磷中毒的方法
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
AU2006212738B2 (en) 2005-02-09 2012-04-05 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
JP2008533021A (ja) * 2005-03-08 2008-08-21 サウンド ファーマシューティカルズ インコーポレイテッド 癌を治療するための方法および組成物
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
EP1888728A4 (en) 2005-05-04 2010-07-14 Pronova Biopharma Norge As Fatty acid analogues, D.H. DHA DERIVATIVES FOR USE AS A MEDICAMENT
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
EP1951248A4 (en) * 2005-11-14 2011-05-25 Peter D Winch NEW COLORED SOLUTIONS OF INJECTABLE MEDICINAL PRODUCTS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
KR101424832B1 (ko) * 2006-05-16 2014-08-06 길리애드 사이언시즈, 인코포레이티드 악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
ES2393933T3 (es) 2006-07-17 2013-01-02 Ramot, At Tel Aviv University Ltd. Conjugados que comprenden un fármaco psicotrópico o un agonista GABA y un ácido orgánico y su uso para el tratamiento del dolor y otros transtornos del SNC
US20080248135A1 (en) * 2006-07-28 2008-10-09 Collegium Pharmaceutical, Inc. Combination Therapy for Otitis with Antiseptic and pH Adjustment
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP5552313B2 (ja) 2006-11-01 2014-07-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物
PT2125786E (pt) * 2006-12-21 2011-04-21 Pfizer Prod Inc Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1hpirazol- 3-il)fenoxi)metil)quinolina
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
WO2008112479A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl] -pyrrole-2, 5-di one
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
HUE029236T2 (en) * 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
BRPI0817234A2 (pt) * 2007-09-26 2014-09-30 Sinai School Medicine Análogos de azacitidina e seus usos
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
EP2220098A2 (en) * 2007-12-12 2010-08-25 Ultimorphix Technologies B.v. Solid forms of tenofovir disoproxil
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
EP2276755A4 (en) 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
NZ589883A (en) * 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
SI2315740T1 (en) 2008-07-08 2018-03-30 Catabasis Pharmaceuticals, Inc. Fatty acids acetylated salicylates and their uses
AU2009268681B2 (en) * 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CN102232070A (zh) * 2008-12-01 2011-11-02 塔加西普特公司 (r)-5-((e)-2-(吡咯烷-3-基乙烯基)嘧啶的合成和新的盐形式
AU2009324495B2 (en) * 2008-12-11 2015-12-24 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
RS53041B (sr) * 2008-12-18 2014-04-30 Novartis Ag Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
EP2416650B1 (en) * 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
DK2433124T3 (en) * 2009-05-19 2017-06-19 Vivia Biotech Sl PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
DK2521447T3 (en) * 2010-01-08 2017-09-18 Catabasis Pharmaceuticals Inc Fatty Acid Fumarates and Their Uses
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012154554A1 (en) * 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
PH12014500316B1 (en) 2011-09-19 2018-10-03 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
WO2013168021A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104225615B (zh) * 2014-09-24 2017-02-01 东南大学 一种紫杉醇类磷脂化合物、其药物组合物及应用
WO2016198971A1 (en) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
CA3017367A1 (en) * 2016-03-15 2017-09-21 Vitality Biopharma, Inc. Methods and compositions for the treatment of demyelinating disorders
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
CA3097384A1 (en) 2018-04-17 2019-10-24 Cardurion Pharmaceuticals, Llc Meglumine salts of thienopyrimidines
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CA3131977C (en) * 2019-03-22 2022-04-26 Integrated Nanotherapeutics Inc. Lipid conjugate prepared from scaffold moiety
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN119606959A (zh) * 2024-12-26 2025-03-14 典晶医药(无锡)有限公司 Tazofelone与紫杉类药物的组合物在治疗实体瘤中的应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449A (en) * 1837-11-11 Improvement in the mode of preparing paint for the protection of buildings against fire
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621048A (en) * 1968-03-14 1971-11-16 Colgate Palmolive Co Quaternary ammonium compounds
US4218234A (en) * 1972-12-07 1980-08-19 Novex Rt. Soil conditioners
SU477159A1 (ru) 1973-07-27 1975-07-15 Всесоюзный научно-исследовательский институт фитопатологии Способ получени амидофосфорилоксиэтиламидов карбоновых кислот
AR208187A1 (es) 1973-12-05 1976-12-09 Pfizer Metodo para la preparacion derivados de n-carbamoil-2-feniletensulfonamida
FR2298332A1 (fr) 1975-01-22 1976-08-20 Asahi Chemical Ind Nouveaux derives de 5-fluorouraciles
JPS5186479A (en) 1975-01-22 1976-07-29 Asahi Chemical Ind 55 furuororashirujudotainoseizohoho
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4351831A (en) * 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4185095A (en) 1977-11-23 1980-01-22 The Massachusetts General Hospital Nerve growth factor
US4287184A (en) 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
CH622660GA3 (enExample) 1978-08-18 1981-04-30
JPS5553208A (en) 1978-10-13 1980-04-18 Mitsubishi Chem Ind Ltd Insecticide
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4408052A (en) 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja) 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
US4558049A (en) 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
JPS59204175A (ja) 1983-04-28 1984-11-19 Terumo Corp ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤
AU591451B2 (en) 1983-08-01 1989-12-07 Mclean Hospital Corporation, The Gamma amino butyric acid esters
WO1985001729A1 (fr) * 1983-10-20 1985-04-25 Terumo Kabushiki Kaisha Derives de 5-fluoro-uracyle et medicament les contenant
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4868161A (en) * 1984-06-29 1989-09-19 City Of Hope Method for promoting nerve regeneration
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
JPS61204136U (enExample) 1985-06-05 1986-12-23
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5246726A (en) 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
ZA886890B (en) 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US5420276A (en) 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
JPH01153629A (ja) 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd 制癌剤
JPH01203331A (ja) 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
JPH01287022A (ja) 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd 抗癌剤耐性克服剤
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
JP2612619B2 (ja) 1988-12-14 1997-05-21 財団法人相模中央化学研究所 含リン化合物よりなる経皮吸収促進剤
CH676909A5 (enExample) 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
GB9001121D0 (en) 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
WO1992016554A1 (en) 1991-03-14 1992-10-01 The University Of Melbourne Protein allergens of the species cynodon dactylon
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
DE4122722A1 (de) 1991-07-06 1993-01-07 Schering Ag Verfahren zur herstellung von indol-derivaten
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
AU3243393A (en) 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5369191A (en) * 1992-01-23 1994-11-29 Kureha Kagaku Kogyo K.K. Aromatic thioether ketone/thioether sulfone copolymer and production process thereof
IT1254515B (it) * 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
IT1254517B (it) * 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
US5214062A (en) 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (ja) 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
DE4224737A1 (de) 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5352596A (en) 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (fr) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2698269B1 (fr) 1992-11-24 1995-01-06 Inst Nat Sante Rech Med Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
AU5574094A (en) * 1992-11-30 1994-06-22 Biosignal Kutato-Fejleszto Kft. Polyunsaturated fatty acyl-peptide composition
US5496714A (en) 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
GB9304746D0 (en) 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (fr) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5480799A (en) 1993-12-10 1996-01-02 The University Of North Carolina At Chapel Hill Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH0815133A (ja) 1994-06-29 1996-01-19 Hitachi Ltd 分析素子
FR2721928A1 (fr) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
JPH0827010A (ja) 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
EP0952841A4 (en) * 1994-08-05 2000-11-02 Molecular Structural Biotechno BIOMOLECULAR COMPLEXES FOR TARGETED TRANSPORTATION OF MEDICINAL PRODUCTS IN SPECIAL REGIONS
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
JPH08163991A (ja) 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd タキサン型ジテルペンの製造方法
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
RU2166512C2 (ru) 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
CA2213000A1 (en) 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JPH0925231A (ja) 1995-07-13 1997-01-28 Sagami Chem Res Center 癌転移抑制剤
JPH0930963A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
US5952317A (en) * 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
AU717238B2 (en) 1995-09-21 2000-03-23 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JP4172726B2 (ja) 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
AU770519B2 (en) 1996-05-22 2004-02-26 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
AU735438B2 (en) 1996-11-12 2001-07-05 Medivir Ab Nucleosides
JPH10168047A (ja) 1996-12-04 1998-06-23 Kao Corp アミド誘導体及びこれを含有する外用剤組成物
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US6153653A (en) 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
GB9804361D0 (en) 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
KR20020000147A (ko) 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
US6184164B1 (en) * 1999-04-28 2001-02-06 The University Of Houston Bimodal silicon nitride-bas ceramic composites
WO2000067802A1 (en) 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6459645B2 (en) 1999-09-30 2002-10-01 Intel Corporation VPX bank architecture
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统

Also Published As

Publication number Publication date
US20040180949A1 (en) 2004-09-16
US7199151B2 (en) 2007-04-03
WO1997044063A2 (en) 1997-11-27
ES2222514T3 (es) 2005-02-01
JP2000514405A (ja) 2000-10-31
DE69730217D1 (de) 2004-09-16
DK0909183T3 (da) 2004-12-20
EP0909183A2 (en) 1999-04-21
CA2255614A1 (en) 1997-11-27
EP0909183B1 (en) 2004-08-11
DE69730217T2 (de) 2005-07-28
WO1997044063A3 (en) 1998-02-26
CA2255614C (en) 2009-12-15
US20020010208A1 (en) 2002-01-24
US5795909A (en) 1998-08-18
EP1466628A1 (en) 2004-10-13
ATE273025T1 (de) 2004-08-15
AU725759B2 (en) 2000-10-19
AU3142597A (en) 1997-12-09
US6602902B2 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
US5795909A (en) DHA-pharmaceutical agent conjugates of taxanes
US8314077B2 (en) Fatty acid-pharmaceutical agent conjugates
US8513304B2 (en) Topical formulation
US9308181B2 (en) Topical formulations, systems and methods
US8263125B2 (en) Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US7976871B2 (en) Modified release composition of highly soluble drugs
US8268352B2 (en) Modified release composition for highly soluble drugs
US20210322447A1 (en) Transdermal micro-dosing delivery of psychedelics derivatives
US20030059471A1 (en) Oral delivery formulation
US20080319092A1 (en) Transdermal Drug Delivery Formulation
US9642912B2 (en) Topical formulations for treating skin conditions
US20150306230A1 (en) Drug delivery vehicles comprising cellulose derivatives, starch derivatives, and combinations thereof
KR20220126286A (ko) 전구약물 조성물 및 치료 방법
EP2291174A1 (en) Biocompatible oligomer-polymer compositions
WO1999030690A1 (en) Oral delivery formulation
CA3208345A1 (en) Prodrug compositions and methods of treatment
AU770519B2 (en) DHA-pharmaceutical agent conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040528

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091029

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121106

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121106

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131106

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees